- Open Access
ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells
© Hagiya et al; licensee BioMed Central Ltd. 2011
- Received: 20 November 2010
- Accepted: 17 March 2011
- Published: 17 March 2011
Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4+ T-cells caused by human T-cell leukemia virus type 1 (HTLV-1). The HTLV-1 bZIP factor (HBZ) gene, which is encoded by the minus strand of the viral genome, is expressed as an antisense transcript in all ATL cases. By using yeast two-hybrid screening, we identified activating transcription factor 3 (ATF3) as an HBZ-interacting protein. ATF3 has been reported to be expressed in ATL cells, but its biological significance is not known.
Immunoprecipitation analysis confirmed that ATF3 interacts with HBZ. Expression of ATF3 was upregulated in ATL cell lines and fresh ATL cases. Reporter assay revealed that ATF3 could interfere with the HTLV-1 Tax's transactivation of the 5' proviral long terminal repeat (LTR), doing so by affecting the ATF/CRE site, as well as HBZ. Suppressing ATF3 expression inhibited proliferation and strongly reduced the viability of ATL cells. As mechanisms of growth-promoting activity of ATF3, comparative expression profiling of ATF3 knockdown cells identified candidate genes that are critical for the cell cycle and cell death, including cell division cycle 2 (CDC2) and cyclin E2. ATF3 also enhanced p53 transcriptional activity, but this activity was suppressed by HBZ.
Thus, ATF3 expression has positive and negative effects on the proliferation and survival of ATL cells. HBZ impedes its negative effects, leaving ATF3 to promote proliferation of ATL cells via mechanisms including upregulation of CDC2 and cyclin E2. Both HBZ and ATF3 suppress Tax expression, which enables infected cells to escape the host immune system.
- Long Terminal Repeat
- Cdc2 Gene
- Ccne2 Gene
Adult T-cell leukemia (ATL) is an aggressive CD4+ T-cell malignancy caused by human T-cell leukemia virus type 1 (HTLV-1) [1–5]. In the plus strand of its genome, HTLV-1 encodes the regulatory proteins Tax and Rex and the accessory proteins p12, p30, and p13. The HTLV-1 basic leucine zipper factor (HBZ) gene is expressed as an antisense transcript. It has been reported that HBZ is consistently expressed and remains intact in all ATL cases and HTLV-1-infected individuals [6, 7], where it promotes cell proliferation [6, 8].
The HBZ gene is expressed as two isoforms: spliced HBZ (sHBZ) and unspliced HBZ (usHBZ) [9–12]. The expression of sHBZ in T-cells promotes T-cell proliferation whereas that of usHBZ does not [8, 12]. HBZ was reported to repress Tax-mediated transactivation of viral transcription from the HTLV-1 promoter by dimerizing with transcription factors including cyclic AMP response element-binding protein 2 (CREB2), and members of the Jun family [10, 13–16]. HBZ also promotes the degradation, directly and without ubiquitination, of some proteins that interact with HBZ . Thus, HBZ interacts with host factors and modulates their function, which is likely to contribute to persistent infection of HTLV-1 in vivo and clonal expansion of infected cells.
Activating transcription factor 3 (ATF3) is a member of the ATF/cyclic AMP response element-binding (CRE) family of transcription factors . ATF3 is an adaptive response gene whose expression is regulated by changes in the extra- or intracellular environment. ATF3 activates signals including DNA damage , anoxia , hypoxia , and represses others, including inflammation . It can form homodimers or hetrodimers with other cellular bZIP transcription factors, including ATF2, c-Jun, JunB, and JunD, and exerts pleiotropic functions through ATF/CRE and AP-1 sites depending on cell type. It has also been pointed out that the ATF3 gene has a potential dichotomous role in cancer development : it has pro-apoptotic functions, like a tumor suppressor, but at the same time induces cell proliferation, like an oncogene. It has been reported as up-regulated in malignant breast cancer cells , Hodgkin cells , and prostate cancer cells  where it is associated with proliferation. Transgenic mice overexpressing ATF3 in basal epithelial cells develop basal cell carcinomas . Up-regulation of ATF3 is also reported in ATL cells , yet the biological significance in ATL is not known. Moreover, the question of how ATF3 induces proliferation of cancer cells remains unsolved.
In the process of elucidating the function of sHBZ in T-cells [6, 12, 28], we identified ATF3 as a sHBZ-interacting protein. In this study, we characterized the role of ATF3 in ATL cells. ATF3 was constitutively expressed in ATL cell lines and fresh ATL cases. ATF3 could repress Tax-mediated transactivation through ATF/CRE sites. Expression of ATF3 was linked to proliferation of ATL cells via upregulation of cell cycle-associated genes and down-regulation of proapoptotic genes. Furthermore, while ATF3 alone enhanced p53 stability, and therefore activation; sHBZ inhibited this function.
Identification of ATF3 as a sHBZ interacting protein
The ATF3 promoter is constitutively activated in ATL cell lines
Suppressive effects of ATF3 on cellular and viral ATF/CRE sites
ATF3 has growth promoting activity in ATL cells
Transcriptional profile of ATF3 KD MT-4 cell
We confirmed the expression of several up-regulated genes by RT-PCR to validate the results of the DNA microarray (Figure 5B). Suppressed expression of ATF3 increased the number of transcripts of proapoptotic genes, Bim and Harakiri. In contrast, cell division cycle 2 (CDC2) and cyclin E2 (CCNE2), which control the cell transition from G1 phase to S phase , were down-regulated in ATF3-KD cells. This is the first report that ATF3 affects the expression of these genes.
CDC2 is a direct target of ATF3
Since KD of ATF3 impairs the G1/S transition, we focused on cdc2 and ccne2 gene expression. Quantitative analysis by real-time PCR confirmed that transcription of both the cdc2 and ccne2 genes was down-regulated in ATF3 KD cells compared to control cells (Figure 5C). The cdc2 gene expression was significantly decreased by KD of ATF3, so cdc2 gene was chosen for further studies. To study whether the effect of ATF3 on the cdc2 gene is direct or indirect, we investigated the binding of ATF3 to the promoter region of the cdc2 gene (Figure 5D). This region contains two putative binding sites for ATF3, an AP-1 site near the transcription start site, and an ATF/CRE site farther 5'-ward (Figure 5D). A chromatin immunoprecipitation assay detected ATF3 bound to the proximal AP-1 site, but ATF3 bound to ATF site was non-specific (Figure 5E). Transient transfection of Jurkat T cells by electroporation with a vector expressing ATF3 up-regulated the expression of cdc2 mRNA (Figure 5F). These results indicate that ATF3 directly activates transcription of the cdc2 gene.
sHBZ inhibited the augmentation of p53 transcriptional activity by ATF3
In this study, a yeast two-hybrid system identified ATF3 as a binding partner of the HTLV-1 sHBZ protein. Aberrant expression of ATF3 has been reported in classical Hodgkin lymphoma (cHL) and malignant prostate cancer cell [24, 25], where it is associated with increased proliferation. In addition, increased expression of ATF3 was also reported in ATL cases . However, the mechanism by which ATF3 promotes proliferation of cancer cells remained unknown. In this study, we demonstrated that increased expression of ATF3 was linked to proliferation via enhanced transcription of the cdc2 and ccne2 genes, along with suppressed expression of proapoptotic factors including Harakiri, and Bim. ATF3 indeed bound to the promoter region of the cdc2 gene and enhanced its transcription. Thus, ATF3 modulates transcription of cellular genes associated with proliferation and apoptosis.
ATF3 has been reported to act as transcriptional repressor of ATF/CRE sequences. In this study, we found that ATF3 suppressed activation, by the viral factor Tax, of transcription from CRE-like sequences in the 5'LTR. Tax, itself transcribed from the 5'LTR, is a major target of cytotoxic T-lymphocytes in vivo . Therefore, suppression of tax gene transcription could benefit the survival of ATL cells, by allowing them to escape a cytotoxic T-lymphocyte response. In contrast to the tax gene, ATL cells need to express the HBZ gene transcripts for their proliferation . HBZ is transcribed from the 3'LTR, and therefore unaffected by ATF3 suppression of the 5'LTR. By suppressing viral gene transcription through the 5'LTR, then, ATF3 modulates viral gene expression, favoring expression of the HBZ gene over the tax gene. Enforced expression of ATF3 in prostate cancer cells induces cell proliferation and accelerates progression from the G1- to S-phase of the cell cycle . The same study also showed that KD of ATF3 expression decreased cells in S phase while it increased cells in G1 phase . In addition, impaired G1/S transition in c-myc null cells was partially recovered by ATF3 expression , indicating the role of ATF3 in G1/S transition.
In this report, we present evidence that the expression of ATF3 is associated with G1/S progression via enhanced transcription of the cdc2 and ccne2 genes, and possibly others. In particular, ATF3 bound the CDC2 promoter directly. The cdc2 gene plays a key role in the transition from the G1 phase to the S phase , and from the G2 phase to the M phase. The ccne2 gene is reported to be highly expressed in a number of human primary tumors including breast, ovary, uterus, brain, and lung . Our results now open the possibility that ccne2, as well as cdc2, may contribute to ATL as well.
Independent of its cell cycle-promoting function, ATF3 also acts like a tumor suppressor, enhancing p53 transcriptional activity by inhibiting its ubiquitin-mediated degradation [31, 38]. ATF3 neither interferes with the p53-MDM2 interaction nor blocks the E3 ligase activity of MDM2, suggesting that binding of ATF3 to p53 likely induces a conformational change of p53 that inhibits ubiquitination [31, 38]. Since ATF3 is an adaptive response gene that responds to extra or intracellular changes, ATF3 stabilization of p53 counters cellular stress due to environmental insult and ensures genomic integrity [31, 38]. Given that p53 is mutated in only about 30% of ATL cases [43–45], and in fact the expression level of p53 protein increases in ATL cells , how is ATF3's p53-stabilizing activity consistent with the chromosome instability often observed in ATL cells ? In fact, post-translational inactivation of p53 is critical to understanding ATL development. A viral protein, Tax, can functionally inactivate p53 by competing for binding to E-box , as well as other mechanisms . However, Tax is not expressed in many ATL cases, due to genetic and epigenetic changes of the HTLV-1 provirus [5, 50], including nonsense mutations generated by APOBEC3G . Mechanisms other than Tax must therefore interfere with p53 signaling. As shown in this study, sHBZ binds to ATF3-p53 complexes. With these interactions, sHBZ reduces ATF3's ability to enhance p53 function. HTLV-1 is not unique in deploying viral proteins to perturb p53 function. The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus, for example, binds to von Hippel-Lindau factor and targets it for degradation. The human papilloma virus-encoded E6 protein binds to the cellular E6-associated protein (E6AP), an ubiquitin ligase that targets p53 for destruction. In fact, this interaction is blocked by ATF3, revealing another way in which ATF3 reinforces p53 signaling .
In HTLV-1's case, sHBZ perturbs one ATF3 function - p53 stabilization - that might slow the proliferation of infected cells, while leaving other functions - promotion of G1/S transition, and repression of provirus transcription - unaffected. HTLV-1 reproduces mainly by promoting the clonal expansion of infected cells, rather than by producing new virus particles. As such, the potential benefits to the virus of modulating ATF3 function in this way are clear: ATF3, in combination with sHBZ, encourages infected cells to progress through the G1/S phase transition, unimpeded by a ATF3-p53 response, and free from detection by host immune cells that might recognize viral antigens transcribed from the 5'LTR.
This study reveals a role of ATF3 in regard to proliferation and viral gene transcription in ATL cells. The combined effects of ATF3 and sHBZ allow ATL cells to survive in vivo, and could be a target of therapy for this malignant disease.
All T-cell lines and ATL cell lines were grown in RPMI 1640 supplemented with 10% fetal bovine serum and antibiotics. 293FT cells were cultured in Dulbecco modified Eagle medium supplemented with 10% FBS and 500 μg/ml G418.
A yeast two-hybrid screen was performed by Hybrigenics (http://www.hybrigenics.com) on a random-primed Leukocytes and Activated Mononuclear Cells cDNA library using HBZ as bait.
The ATF3 coding sequence was amplified by polymerase chain reaction (PCR) and was cloned into pCMV-Tag2 (Stratagene, La Jolla, CA), or pcDNA3 (Invitrogen, Carlsbad, CA). Expression vectors for sHBZ , its deletion mutants , reporter plasmids pWT-luc, pLTR-luc [34, 35], and pG13-luc  were described previously. pCREx4-luc was purchased from Stratagene (La Jolla, CA). Luciferase assay was performed as described previously .
Cells were infected with an shRNA lentiviral vector (Invitrogen) directed against ATF3. The following target sequence were chosen: ATF3_KD1 5'-GAGCTGAGGTTTGCCATCC-3', ATF3_KD2 5'-GTGTATTGTCCGGGCTCAG-3' and ATF3_KD3 5'-GAACGAGAAGCAGCATTTG-3' as described previously . Control cells were infected with an shRNA retroviral vector expressing a nonsilencing construct provided also by Invitrogen that does not target any known vertebrate gene as described in manufacture's instruction.
Proliferation assay and cell cycle analysis
Cell viability was measured with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay . In cell cycle analysis, after cell fixation with 70% ethanol, cells were suspended in 50 μg/ml Propidium Iodide solution containing 0.1 mg/ml RNase A and 0.05% Triton X-100 for 40 min at 37℃ and were analyzed by flow cytometry.
The tissue specimens were obtained from human lymph nodes filed at the Department of Pathology at Kurume University. The study of clinical samples was approved by the local research ethics committee of the Kurume University. Tissue samples were fixed in 10% formalin in phosphate buffer and then embedded in paraffin and analyzed by immunohistochemical methods to determine ATF3 expression. Images were captured using a Provis AX80 microscope equipped with an OLYMPUS DP70 digital camera, and detected using a DP manager system (Olympus, Tokyo, Japan).
Electroporation was performed with Neon™ transfection system (Invitrogen). Electroporation parameters for Jurkat cell were those recommended by Invitrogen.
RNA isolation, Reverse transcriptase (RT)-PCR, real-time PCR
Total RNAs were extracted using TRIZOL (Invitrogen) according to the manufacturer's protocol. Primers for the ATF3, HBZ, and tax genes were described previously[6, 32] The Power SYBR Green PCR Master Mix (Qiagen, Venlo, Netherlands) was used in real-time PCR analysis in triplicate with β-actin as an internal control. In general, the threshold cycle numbers for actin in different cells are very close, and the relative mRNA level for the gene of interest is calculated as 2[Ct (actin)-Ct (gene)], where Ct is threshold cycle number. Primers were 5'-TGGAAACCAGGAAGCCTAGC-3' (sense) and 5'-GAAATTCGTTTGGCTGGATCAT-3' (antisense) for CDC2; 5'-GAATGTCAAGACGAAGTA-3' (sense) and 5'-ATGAACATATCTGCTCTC-3' (antisense) for CCNE2.
Oligonucleotide microarray analysis
RNA processing and hybridization to U133 Plus 2.0 GeneChip microarrays were performed according to the manufacturer's protocol (Affimetrix, Santa Clara, CA). Data were analyzed with the GeneSpring GX 10 software (Agilent Technologies, Palo Alto, CA).
Immunoprecipitation (IP) and immunoblotting
Cell lysates were incubated with anti-His-Tag (PM002) (MBL, Nagoya, Japan), anti-c-myc (clone 9E10) and anti-FLAG M2 antibodies (Sigma-Aldrich, St Louis, MO) for 1 hour at 4°C, and immune complexes were incubated with protein G-sepharose (GE Healthcare, Little Chalfont, UK) for 1 hour at 4°C. The following antibodies were used for immunoblot: anti-ATF3 (Santa Cruz Biotechnologies, Santa Cruz, CA); anti-His-Tag (PM002) (MBL); anti-FLAG M2 and anti-p53-biotin (Sigma-Aldrich); peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG or streptavidin-biotinylated horseradish peroxidase complex (GE Healthcare). To detect ATF3 using anti-ATF3 antibody, Immuno-enhancer (Wako, Osaka, Japan) was used.
Cells were lysed in lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, and protease inhibitor cocktail), and incubated for 1 hour at 4°C. For the first IP, after clarification by low-speed centrifugation, the supernatants were incubated with anti-FLAG M2 Affinity gel (Sigma-Aldrich) for 3 h at 4°C. The FLAG-agarose beads were then washed with lysis buffer and the bound proteins were eluted with FLAG elution buffer (50 mM Tris-HCl, 150 mM NaCl, and 0.5 mg/ml FLAG peptide [Sigma]) for 1 hr at 4°C. For the second IP, after the FLAG-agarose beads were removed by centrifugation, the supernatants were incubated with anti-c-Myc for 1 hr at 4°C.
We thank Aaron Coutts for his valuable suggestions and kind revision of the manuscript. This study was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan, a grant from the NOVARTIS foundation to MM, and a grant from the Naito Foundation to YS.
- Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H: Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977, 50: 481-492.PubMedGoogle Scholar
- Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980, 77: 7415-7419. 10.1073/pnas.77.12.7415.PubMed CentralView ArticlePubMedGoogle Scholar
- Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I: Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 1981, 78: 6476-6480. 10.1073/pnas.78.10.6476.PubMed CentralView ArticlePubMedGoogle Scholar
- Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982, 79: 2031-2035. 10.1073/pnas.79.6.2031.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007, 7: 270-280. 10.1038/nrc2111.View ArticlePubMedGoogle Scholar
- Satou Y, Yasunaga J, Yoshida M, Matsuoka M: HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA. 2006, 103: 720-725. 10.1073/pnas.0507631103.PubMed CentralView ArticlePubMedGoogle Scholar
- Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, Arimura K, Matsuoka M, Ohara Y: In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology. 2009, 6: 19-10.1186/1742-4690-6-19.PubMed CentralView ArticlePubMedGoogle Scholar
- Arnold J, Zimmerman B, Li M, Lairmore MD, Green PL: Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation. Blood. 2008, 112: 3788-3797. 10.1182/blood-2008-04-154286.PubMed CentralView ArticlePubMedGoogle Scholar
- Murata K, Hayashibara T, Sugahara K, Uemura A, Yamaguchi T, Harasawa H, Hasegawa H, Tsuruda K, Okazaki T, Koji T, et al: A novel alternative splicing isoform of human T-cell leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization. J Virol. 2006, 80: 2495-2505. 10.1128/JVI.80.5.2495-2505.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, Mesnard JM: The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol. 2002, 76: 12813-12822. 10.1128/JVI.76.24.12813-12822.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Larocca D, Chao LA, Seto MH, Brunck TK: Human T-cell leukemia virus minus strand transcription in infected T-cells. Biochem Biophys Res Commun. 1989, 163: 1006-1013. 10.1016/0006-291X(89)92322-X.View ArticlePubMedGoogle Scholar
- Yoshida M, Satou Y, Yasunaga J, Fujisawa J, Matsuoka M: Transcriptional control of spliced and unspliced human T-cell leukemia virus type 1 bZIP factor (HBZ) gene. J Virol. 2008, 82: 9359-9368. 10.1128/JVI.00242-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Basbous J, Arpin C, Gaudray G, Piechaczyk M, Devaux C, Mesnard JM: The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem. 2003, 278: 43620-43627. 10.1074/jbc.M307275200.View ArticlePubMedGoogle Scholar
- Lemasson I, Lewis MR, Polakowski N, Hivin P, Cavanagh MH, Thebault S, Barbeau B, Nyborg JK, Mesnard JM: Human T-cell leukemia virus type 1 (HTLV-1) bZIP protein interacts with the cellular transcription factor CREB to inhibit HTLV-1 transcription. J Virol. 2007, 81: 1543-1553. 10.1128/JVI.00480-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Thebault S, Basbous J, Hivin P, Devaux C, Mesnard JM: HBZ interacts with JunD and stimulates its transcriptional activity. FEBS Lett. 2004, 562: 165-170. 10.1016/S0014-5793(04)00225-X.View ArticlePubMedGoogle Scholar
- Matsumoto J, Ohshima T, Isono O, Shimotohno K: HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein. Oncogene. 2005, 24: 1001-1010. 10.1038/sj.onc.1208297.View ArticlePubMedGoogle Scholar
- Isono O, Ohshima T, Saeki Y, Matsumoto J, Hijikata M, Tanaka K, Shimotohno K: Human T-cell leukemia virus type 1 HBZ protein bypasses the targeting function of ubiquitination. J Biol Chem. 2008, 283: 34273-34282. 10.1074/jbc.M802527200.PubMed CentralView ArticlePubMedGoogle Scholar
- Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U: ATF3 and stress responses. Gene Expr. 1999, 7: 321-335.PubMedGoogle Scholar
- Turchi L, Aberdam E, Mazure N, Pouyssegur J, Deckert M, Kitajima S, Aberdam D, Virolle T: Hif-2alpha mediates UV-induced apoptosis through a novel ATF3-dependent death pathway. Cell Death Differ. 2008, 15: 1472-1480. 10.1038/cdd.2008.74.View ArticlePubMedGoogle Scholar
- Ameri K, Hammond EM, Culmsee C, Raida M, Katschinski DM, Wenger RH, Wagner E, Davis RJ, Hai T, Denko N, Harris AL: Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway. Oncogene. 2007, 26: 284-289. 10.1038/sj.onc.1209781.View ArticlePubMedGoogle Scholar
- Hai T, Hartman MG: The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene. 2001, 273: 1-11. 10.1016/S0378-1119(01)00551-0.View ArticlePubMedGoogle Scholar
- Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Roach JC, Kennedy K, Hai T, Bolouri H, Aderem A: Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature. 2006, 441: 173-178. 10.1038/nature04768.View ArticlePubMedGoogle Scholar
- Yin X, Dewille JW, Hai T: A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene. 2008, 27: 2118-2127. 10.1038/sj.onc.1210861.View ArticlePubMedGoogle Scholar
- Janz M, Hummel M, Truss M, Wollert-Wulf B, Mathas S, Johrens K, Hagemeier C, Bommert K, Stein H, Dorken B, Bargou RC: Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood. 2006, 107: 2536-2539. 10.1182/blood-2005-07-2694.View ArticlePubMedGoogle Scholar
- Pelzer AE, Bektic J, Haag P, Berger AP, Pycha A, Schafer G, Rogatsch H, Horninger W, Bartsch G, Klocker H: The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol. 2006, 175: 1517-1522. 10.1016/S0022-5347(05)00651-8.View ArticlePubMedGoogle Scholar
- Wang A, Arantes S, Conti C, McArthur M, Aldaz CM, MacLeod MC: Epidermal hyperplasia and oral carcinoma in mice overexpressing the transcription factor ATF3 in basal epithelial cells. Mol Carcinog. 2007, 46: 476-487. 10.1002/mc.20298.View ArticlePubMedGoogle Scholar
- Kamioka M, Imamura J, Komatsu N, Daibata M, Sugiura T: Testican 3 expression in adult T-cell leukemia. Leuk Res. 2009, 33: 913-918. 10.1016/j.leukres.2008.11.006.View ArticlePubMedGoogle Scholar
- Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M, Matsuoka M: Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood. 2009, 113: 2755-2764. 10.1182/blood-2008-06-161729.View ArticlePubMedGoogle Scholar
- Perez S, Vial E, van Dam H, Castellazzi M: Transcription factor ATF3 partially transforms chick embryo fibroblasts by promoting growth factor-independent proliferation. Oncogene. 2001, 20: 1135-1141. 10.1038/sj.onc.1204200.View ArticlePubMedGoogle Scholar
- Tamura K, Hua B, Adachi S, Guney I, Kawauchi J, Morioka M, Tamamori-Adachi M, Tanaka Y, Nakabeppu Y, Sunamori M, et al: Stress response gene ATF3 is a target of c-myc in serum-induced cell proliferation. EMBO J. 2005, 24: 2590-2601. 10.1038/sj.emboj.7600742.PubMed CentralView ArticlePubMedGoogle Scholar
- Yan C, Lu D, Hai T, Boyd DD: Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. EMBO J. 2005, 24: 2425-2435. 10.1038/sj.emboj.7600712.PubMed CentralView ArticlePubMedGoogle Scholar
- Miyazaki K, Inoue S, Yamada K, Watanabe M, Liu Q, Watanabe T, Adachi MT, Tanaka Y, Kitajima S: Differential usage of alternate promoters of the human stress response gene ATF3 in stress response and cancer cells. Nucleic Acids Res. 2009, 37: 1438-1451. 10.1093/nar/gkn1082.PubMed CentralView ArticlePubMedGoogle Scholar
- Liang G, Wolfgang CD, Chen BP, Chen TH, Hai T: ATF3 gene. Genomic organization, promoter, and regulation. J Biol Chem. 1996, 271: 1695-1701. 10.1074/jbc.271.3.1695.View ArticlePubMedGoogle Scholar
- Fujisawa J, Toita M, Yoshida M: A unique enhancer element for the trans activator (p40tax) of human T-cell leukemia virus type I that is distinct from cyclic AMP- and 12-O-tetradecanoylphorbol-13-acetate-responsive elements. J Virol. 1989, 63: 3234-3239.PubMed CentralPubMedGoogle Scholar
- Suzuki T, Fujisawa JI, Toita M, Yoshida M: The trans-activator tax of human T-cell leukemia virus type 1 (HTLV-1) interacts with cAMP-responsive element (CRE) binding and CRE modulator proteins that bind to the 21-base-pair enhancer of HTLV-1. Proc Natl Acad Sci USA. 1993, 90: 610-614. 10.1073/pnas.90.2.610.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen BP, Liang G, Whelan J, Hai T: ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. J Biol Chem. 1994, 269: 15819-15826.PubMedGoogle Scholar
- Aleem E, Kiyokawa H, Kaldis P: Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol. 2005, 7: 831-836. 10.1038/ncb1284.View ArticlePubMedGoogle Scholar
- Yan C, Boyd DD: ATF3 regulates the stability of p53: a link to cancer. Cell Cycle. 2006, 5: 926-929. 10.4161/cc.5.9.2714.View ArticlePubMedGoogle Scholar
- Yasunaga J, Matsuoka M: Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control. 2007, 14: 133-140.PubMedGoogle Scholar
- Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G, Sato S, Morita M, Kidokoro M, Sugimoto M, et al: Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol. 1991, 3: 761-767. 10.1093/intimm/3.8.761.View ArticlePubMedGoogle Scholar
- Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009, 9: 153-166. 10.1038/nrc2602.View ArticlePubMedGoogle Scholar
- Payton M, Coats S: Cyclin E2, the cycle continues. Int J Biochem Cell Biol. 2002, 34: 315-320. 10.1016/S1357-2725(01)00137-6.View ArticlePubMedGoogle Scholar
- Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, Koeffler HP: Mutations of the p53 gene in adult T-cell leukemia. Blood. 1992, 79: 477-480.PubMedGoogle Scholar
- Cesarman E, Chadburn A, Inghirami G, Gaidano G, Knowles DM: Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood. 1992, 80: 3205-3216.PubMedGoogle Scholar
- Nishimura S, Asou N, Suzushima H, Okubo T, Fujimoto T, Osato M, Yamasaki H, Lisha L, Takatsuki K: p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia. Leukemia. 1995, 9: 598-604.PubMedGoogle Scholar
- Takemoto S, Trovato R, Cereseto A, Nicot C, Kislyakova T, Casareto L, Waldmann T, Torelli G, Franchini G: p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Blood. 2000, 95: 3939-3944.PubMedGoogle Scholar
- Jeang KT, Giam CZ, Majone F, Aboud M: Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem. 2004, 279: 31991-31994. 10.1074/jbc.R400009200.View ArticlePubMedGoogle Scholar
- Suzuki T, Uchida-Toita M, Yoshida M: Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site. Oncogene. 1999, 18: 4137-4143. 10.1038/sj.onc.1202766.View ArticlePubMedGoogle Scholar
- Tabakin-Fix Y, Azran I, Schavinky-Khrapunsky Y, Levy O, Aboud M: Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications. Carcinogenesis. 2006, 27: 673-681. 10.1093/carcin/bgi274.View ArticlePubMedGoogle Scholar
- Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, Tanaka Y, Matsuoka M: Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 2004, 109: 559-567. 10.1002/ijc.20007.View ArticlePubMedGoogle Scholar
- Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, Wain-Hobson S, Vartanian JP, Matsuoka M: APOBEC3G Generates Nonsense Mutations in HTLV-1 Proviral Genomes In Vivo. J Virol. 2010, 84 (14): 7278-87. 10.1128/JVI.02239-09. Epub 2010 May 12PubMed CentralView ArticlePubMedGoogle Scholar
- Cai QL, Knight JS, Verma SC, Zald P, Robertson ES: EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog. 2006, 2: e116-10.1371/journal.ppat.0020116.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang H, Mo P, Ren S, Yan C: Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. J Biol Chem. 2010, 285: 13201-13210. 10.1074/jbc.M109.058669.PubMed CentralView ArticlePubMedGoogle Scholar
- el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 1993, 75: 817-825. 10.1016/0092-8674(93)90500-P.View ArticlePubMedGoogle Scholar
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.